sandimmun innrennslisþykkni, lausn 50 mg/ml
novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml
mercilon tafla 150 míkróg/20 míkróg
n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg
saizen (saizen lq) stungulyf, lausn í rörlykju 5,83 mg/ml
merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 5,83 mg/ml
saizen (saizen lq) stungulyf, lausn í rörlykju 8 mg/ml
merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 8 mg/ml
rybrevant
janssen-cilag international n.v. - amivantamab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
vetergesic vet. stungulyf, lausn 300 míkróg/ml
ceva santé animale* - buprenorphinum hýdróklóríð - stungulyf, lausn - 300 míkróg/ml
femar filmuhúðuð tafla 2,5 mg
novartis healthcare a/s - letrozolum inn - filmuhúðuð tafla - 2,5 mg
genotropin stungulyfsstofn og leysir, lausn 12 mg
pfizer aps - somatropinum inn - stungulyfsstofn og leysir, lausn - 12 mg
genotropin stungulyfsstofn og leysir, lausn 5 mg
pfizer aps - somatropinum inn - stungulyfsstofn og leysir, lausn - 5 mg
letrozol actavis filmuhúðuð tafla 2,5 mg
actavis group ptc ehf. - letrozolum inn - filmuhúðuð tafla - 2,5 mg